Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Annovis Bio (ANVS) is set to report its Q2 2025 earnings on August 13th, with an expected loss of ($0.36) per share for the quarter.
• The company recently reported a narrower loss of ($0.32) EPS, surpassing the consensus estimate of ($0.47) in its previous earnings announcement.
• Analysts have reduced price targets for Annovis Bio, with a current consensus rating of "Buy" and an average price target of $18.00.

Annovis Bio (NYSE:ANVS - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect Annovis Bio to post earnings of ($0.36) per share for the quarter.

Annovis Bio (NYSE:ANVS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.15. On average, analysts expect Annovis Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Annovis Bio Trading Down 3.0%

NYSE ANVS traded down $0.08 on Thursday, reaching $2.59. 103,421 shares of the stock were exchanged, compared to its average volume of 301,118. The firm has a market capitalization of $50.48 million, a PE ratio of -1.20 and a beta of 1.51. Annovis Bio has a one year low of $1.11 and a one year high of $10.54. The company's 50-day simple moving average is $2.68 and its two-hundred day simple moving average is $2.32.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Canaccord Genuity Group cut their target price on Annovis Bio from $26.00 to $17.00 and set a "buy" rating for the company in a research report on Thursday, May 15th. HC Wainwright cut their price objective on shares of Annovis Bio from $30.00 to $12.00 and set a "buy" rating for the company in a report on Monday, June 9th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $18.00.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.